Phaseline

Companies › Faeth Therapeutics

Faeth Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 11 registered trials: 6 Phase 1, 5 Phase 2; Oncology; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sapanisertib
Serine/threonine-protein kinase mTOR inhibitor
MTORPhase 2Endometrial Cancer; HR+ HER2- Breast Cancer; Locally Advanced Bladder Urothelial Carcinoma; Advanced Lymphoma …Sep 2028
Serabelisib
PI3-kinase p110-alpha subunit inhibitor
PIK3CAPhase 2Endometrial Cancer; HR+ HER2- Breast CancerSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02142803SapanisertibPhase 1Adult GlioblastomaOncologyDec 2020
NCT03047213SapanisertibPhase 2Locally Advanced Bladder Urothelial CarcinomaOncologyNov 2026
NCT04250545SapanisertibPhase 1Leptomeningeal NeoplasmOncologyNov 2026
NCT06390865SapanisertibPhase 2Advanced LymphomaOncologyDec 2026
NCT06385496SapanisertibPhase 2Advanced LymphomaOncologyDec 2026
NCT02503722SapanisertibPhase 1Metastatic Lung Non-Small Cell CarcinomaOncologyFeb 2027
NCT06811116SapanisertibPhase 1Advanced Hepatocellular CarcinomaOncologyAug 2027
NCT06463028SapanisertibPhase 2Endometrial CancerOncologySep 2028
NCT06463028SerabelisibPhase 2Endometrial CancerOncologySep 2028
NCT07558733SapanisertibPhase 1HR+ HER2- Breast CancerOncologyMay 2029
NCT07558733SerabelisibPhase 1HR+ HER2- Breast CancerOncologyMay 2029

From the company's SEC filings

Cash and short-term investments of $175m on 2026-09-30; operating cash outflow about $53m a year; runway about 40 months at that burn, to Jan 2030; 4 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MTOR (1) PIK3CA (1)

Companies with the same targets

Eli Lilly Restorbio Celcuity iVascular S.L.U. Palvella Therapeutics Supernus Pharmaceuticals SAPU NANO (US) AstraZeneca Novartis Recursion Pharmaceuticals

Companies built like this

C4 Therapeutics Black Diamond Therapeutics Kyntra Bio Celcuity Teligene US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.